Racura Oncology Ltd has released a press release.
Emerging Companies Specialist Invests in Racura
Earlier from Racura Oncology
- Racura Enters Underwriting Agreement for Options
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
- CPACS Trial Cleared to Escalate to Next RC220 Dose Level
- (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression